Abstract
The issues relating to the licensing of a biopharmaceutical are described. In particular attention is focused on the mind of the regulator who has the responsibility of recommending licensure. There are two key factors which operate on the mind when confronted with such a task: psychology and ethics. The different factors which influence the psychological acceptability of a product for licensure are many and varied; they include perceived need, novelty, education, context and others. Also involved is the regulator’s view of the ethicality of such products and the organisms which make them, with particular reference to those which are genetically engineered. These ethical views are in turn derived by reference to basic systems of ethics which provide guidelines for behavior. It is important for the manufacturers of biopharmaceuticals to be aware of both the psychological and ethical aspects of the regulator’s mind when addressing such individuals with a view to obtaining a license to manufacture a particular biopharmaceutical.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vagelos, P.R. (1991) Are prescription drug prices too high.Science 252: 1080–1084.
de Maris (1993)Review of the Pharmaceutical Industry: Costs. Document No. OTA-H-523 (February 1993), U.S. Government Publication.
Lee, K.B. and Burrill, G.S. (1994)Biotech 95: Reform, Restructure, Renewal, The Ernst and Young Ninth Annual Report on the Biotechnology Industry, p14.
Joint ESACT-IABS meeting on the use of heteroploid and other cell substrates for the production of biologicals. (1982)Developments in Biological Standardization vol 50, Karger, Basel, Switzerland.
Continuous cell lines as substrates for biologicals. (1989)Developments in Biological standardization vol 70, Karger, Basel, Switzerland.
Virological aspects of the safety of biological products (1991)Developments in Biological Standardization, vol 75 Karger, Basel, Switzerland.
Dunlop, D. (1973)Medicines in our time, The Nuffield Provincial Hospital’s Trust, pp 67–89.
Goldenthal, K. (1995) FDA perspective on evaluation of new vaccine technology, In: Vaccines: New Technologies and Applications (Proceedings of a Meeting held in Alexandria, VA, 20–22 March 1995), published by Cambridge Health Institute, Waltham, MA.
Lowrance, W.W. (1976)Of Acceptable Risk, William Kaufmann, Inc., Los Altos CA, pp 75–86.
Kletz, T.A. (1981) Benefits and risks, their assessment in relation to human needs, In: Griffiths, R.F., ed.,Dealing with risk, The planning, management and acceptability of technological risk, Manchester University Press, UK, pp36–53.
Report of a Royal Society Study Group (1983)Risk assessment. The Royal Society, London, pp 94–148.
Singer, P., ed. (1993)A Companion to Ethics, Blackwell, Oxford.
Genesis.1:22.
Evangelicum Vitae (1995) Catholic Truth Society, London.
McNeill, W.H. (1977)Plagues and Peoples, Blackwell, Oxford, UK.
Gorman, C. (1995) Has gene therapy stalled,Time (9 October): pp50–51.
Fenner, F. (1982) A successful eradication campaign. Global eradication of smallpox.Reviews of Infectious Diseases 4: 916–930.
de Quadros, C.A. (1994) Strategies for disease control/eradication in the Americas. In: Cutts, F.T. and Smith, P.G. eds.,Vaccination and World Health, John Wiley & Sons Ltd, New York, pp 17–36.
The State of the World’s Children 1996, UNICEF, Oxford University Press, UK, pp 98–99.
Swartz, R.W. (1985) Penicillins. In: Moo-Young, M. ed.,Comprehensive Biotechnology, vol 3. Pergamon Press, Oxford, UK, pp 8–47.
Kelves, D.J. (1985)In the Name of Eugenics, University of California Press, Berkeley, CA, pp 426.
Rolin, B.E. (1995)The Frankenstein Syndrome, Cambridge University Press, UK, pp 61–2.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spier, R.E. On the acceptability of biopharmaceuticals. Sci Eng Ethics 2, 291–306 (1996). https://doi.org/10.1007/BF02583915
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02583915